MELISSA VITALE: Open Payments
NPI 1952867681 · CHICAGO, IL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$21,634 in 62 payments from 10 companies in 2025. Trend: 2023 $45,685 · 2024 $29,993 · 2025 $21,634
Speaker / faculty: $16,280Travel & lodging: $4,147Food & beverage: $1,207
| Company | Payments | Amount |
|---|---|---|
| Janssen Pharmaceuticals, Inc | 42 | $21,005 |
| ABBVIE INC. | 5 | $199 |
| Teva Pharmaceuticals USA, Inc. | 1 | $125 |
| E.R. Squibb & Sons, L.L.C. | 4 | $69 |
| Otsuka America Pharmaceutical, Inc. | 2 | $68 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $63 |
| Lundbeck LLC | 2 | $44 |
| Corium, LLC | 1 | $26 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
| Bausch Health US, LLC | 1 | $16 |
Products named: INVEGA SUSTENNA, VRAYLAR, UZEDY, REXULTI, COBENFY, CAPLYTA, Azstarys, ABILIFY ASIMTUFII.
Industry payments across IL — which companies pay providers there.
